These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28352421)

  • 1. Effects of Uric Acid on Lipid Levels in CKD Patients in a Randomized Controlled Trial.
    Bowden RG; Shelmadine BD; Moreillon JJ; Deike E; Griggs JO; Wilson RL
    Cardiol Res; 2013 Apr; 4(2):56-63. PubMed ID: 28352421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.
    Shelmadine B; Bowden RG; Wilson RL; Beavers D; Hartman J
    Anadolu Kardiyol Derg; 2009 Oct; 9(5):385-9. PubMed ID: 19819789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The gender features of disorders of composition of lipids of blood serum in patients with chronic pathology of kidneys.].
    Murkamilov IT; Aytabaiev KA; Fomin VV; Murkamilova ZA; Rayimjanov ZR; Redjapova NA; Yusupov FA; Aydarov ZA
    Klin Lab Diagn; 2018; 63(3):152-158. PubMed ID: 30673194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of allopurinol and uric acid normalization on serum lipids hyperuricemic subjects: A systematic review with meta-analysis.
    Castro VMF; Melo AC; Belo VS; Chaves VE
    Clin Biochem; 2017 Dec; 50(18):1289-1297. PubMed ID: 28754333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Lowering Uric Acid Levels Using Allopurinol on Components of Metabolic Syndrome.
    Heimbach EJ; Bowden RG; Griggs JO; Beaujean AA; Doyle EI; Doyle RD
    Cardiol Res; 2012 Apr; 3(2):80-86. PubMed ID: 28348676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
    Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
    Bose B; Badve SV; Hiremath SS; Boudville N; Brown FG; Cass A; de Zoysa JR; Fassett RG; Faull R; Harris DC; Hawley CM; Kanellis J; Palmer SC; Perkovic V; Pascoe EM; Rangan GK; Walker RJ; Walters G; Johnson DW
    Nephrol Dial Transplant; 2014 Feb; 29(2):406-13. PubMed ID: 24042021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial.
    Muir SW; Harrow C; Dawson J; Lees KR; Weir CJ; Sattar N; Walters MR
    Stroke; 2008 Dec; 39(12):3303-7. PubMed ID: 18845806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder.
    Jahangard L; Soroush S; Haghighi M; Ghaleiha A; Bajoghli H; Holsboer-Trachsler E; Brand S
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1210-21. PubMed ID: 24953766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients.
    Shidfar F; Keshavarz A; Jallali M; Miri R; Eshraghian M
    Int J Vitam Nutr Res; 2003 May; 73(3):163-70. PubMed ID: 12847992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Borgi L; McMullan C; Wohlhueter A; Curhan GC; Fisher ND; Forman JP
    Hypertension; 2017 Feb; 69(2):243-248. PubMed ID: 28028194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
    Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function and lipid metabolism in pregnant renal transplant recipients.
    Czajkowski K; Wójcicka-Bentyn J; Sieńko J; Grymowicz M; Smolarczyk R; Malinowska-Polubiec A; Romejko E
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):155-61. PubMed ID: 15140508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study.
    Locatelli F; Dimkovic N; Pontoriero G; Spasovski G; Pljesa S; Kostic S; Manning A; Sano H; Nakajima S
    Nephrol Dial Transplant; 2010 Feb; 25(2):574-81. PubMed ID: 19736246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.